FDA Rules: Updating Drug Testing Methods
This bill has moved out of committee and is now waiting for a vote by the full House of Representatives as of June 17, 2026. While reaching this stage is a significant step, the bill is not guaranteed a floor vote because House leaders must decide to schedule it. It remains active but faces a difficult path forward to become law.
This bill has support from both parties and simply helps the FDA follow a law that was already passed. It fixes technical issues and updates rulebooks to match current policy.
This bill’s path across every version that has carried it.
Reintroduced
Reintroduced from H.R. 7248 (118th), which died when its Congress ended.
H.R. 7248 (118th) →Govbase has not yet run an impact analysis on this legislation.
Received in the Senate.
The Senate has received the House-passed bill and will decide whether to take it up.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H4639)
The House fast-tracked this bill — limited debate, no amendments allowed, but needs two-thirds support to pass.
Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote.
The House fast-tracked this bill — limited debate, no amendments allowed, but needs two-thirds support to pass.
DEBATE - The House proceeded with forty minutes of debate on H.R. 2821.
No votes or news coverage recorded for this bill yet.
Document Type
Congressional Bill
Official Title
FDA Modernization Act 3.0
Analysis generated by AI. Always verify with official sources.